Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.52 USD | +3.12% | +3.75% | +37.10% |
May. 09 | Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating | MT |
May. 08 | Revolution Medicines Q1 Net Loss Narrows | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.10% | 6.32B | |
+46.17% | 54.63B | |
-6.93% | 39.92B | |
+37.07% | 38.82B | |
+13.34% | 26.86B | |
-11.17% | 26.22B | |
-21.77% | 18.78B | |
+25.95% | 12.21B | |
+0.80% | 12.16B | |
+25.57% | 11.94B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Goldman Sachs Adjusts Price Target on Revolution Medicines to $23 From $20, Maintains Neutral Rating